Pathologic Complete Response Predicts Recurrence-Free Survival More Effectively by Cancer Subset: Results From the I-SPY 1 TRIAL—CALGB 150007/150012, ACRIN 6657

PURPOSE: Neoadjuvant chemotherapy for breast cancer provides critical information about tumor response; how best to leverage this for predicting recurrence-free survival (RFS) is not established. The I-SPY 1 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging and...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Esserman, Laura J., Berry, Donald A., DeMichele, Angela, Carey, Lisa, Davis, Sarah E., Buxton, Meredith, Hudis, Cliff, Gray, Joe W., Perou, Charles, Yau, Christina, Livasy, Chad, Krontiras, Helen, Montgomery, Leslie, Tripathy, Debasish, Lehman, Constance, Liu, Minetta C., Olopade, Olufunmilayo I., Rugo, Hope S., Carpenter, John T., Dressler, Lynn, Chhieng, David, Singh, Baljit, Mies, Carolyn, Rabban, Joseph, Chen, Yunn-Yi, Giri, Dilip, van 't Veer, Laura, Hylton, Nola
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2012
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3434983/
https://ncbi.nlm.nih.gov/pubmed/22649152
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.39.2779
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados